



Jazz Pharmaceuticals Quality Improvement Grants:

Improving Guideline Concordant Care for Advanced
HER2+ Gastroesophageal Adenocarcinoma

Request for Proposals

Last Updated: September 4, 2026

Applications Due: October 15, 2026

Link to [Funding Opportunity](#)

Application Portal: everygrant.smapply.us

Quality Improvement Initiative: Improving Guideline Concordant Care for Advanced HER2+ GEA

Purpose

Gastroesophageal adenocarcinoma (GEA) remains a significant global health burden, characterized by aggressive tumor biology and historically poor prognoses. The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of GEA tumors, and these patients can benefit from HER2-targeted therapies, as reflected in current treatment guidelines¹. However, evaluations of treatment patterns for patients with advanced HER2+ gastro-esophageal (GEA) cancer in the United States reveals that only about 60% of patients with HER2+ disease receive HER2 directed therapy as part of first line treatment despite well-established standards of care and treatment guideline recommendations.

To address this gap, Conquer Cancer, the ASCO Foundation and Jazz Pharmaceuticals are collaborating to offer a Quality Improvement funding opportunity for projects that will develop and deliver strategies to improve guideline concordant care to HER2+ gastroesophageal adenocarcinoma (GEA) patients. Projects should be designed to provide meaningful impact for GEA patients and be sustainable and transferable to other settings.

With the goal of this program to improve care and outcomes for GEA patients, applicants are expected to include the patient perspective. This could include collaborating with patient advocates, advocacy groups, or other organizations representing the patients that would be impacted by this work.

Organization Information

This grant program is a collaboration between Jazz Pharmaceuticals and EveryGrant® powered by Conquer Cancer, designed expressly to meet the needs of GEA patients and care providers. Conquer Cancer acts as the primary administrator for the review and evaluation of applications. Grant funding will be provided directly to recipients by Jazz Pharmaceuticals.

Background

GEA represents approximately 3% of all new cancer cases in the US, and it is estimated that 54,000 people in the US will be diagnosed with GEA in 2026. The majority of those patients will be diagnosed at the advanced/metastatic stage, with 5-year median survival of less than 10%.

Approximately 20% of GEA patients are HER2+ and these patients can benefit from HER2-targeted therapies. HER2-targeted treatment regimens have been the first-line standard of care for over 15 years for these patients, as reflected in NCCN and other oncology treatment guidelines. However, real world

¹ Ajani J et al. *J Natl Compr Canc Netw* 2025;23(5):169–191

evidence has shown that up to 40% of advanced HER2+ patients do not receive HER2-targeted therapy as part of a first-line treatment regimen².

While biomarker testing rates for HER2 are ~85% in GEA, analysis of current treatment patterns in the United States demonstrate a clear gap in delivering guideline concordant care. Given the devastating prognosis of this disease, there is urgency to understand and address the gaps in care that have resulted in lack of concordance with treatment guidelines. The ultimate goal of this program is to ensure that patients with HER2+ GEA receive the most effective treatment possible, as soon as possible, for the best outcomes possible.

Nothing in this RFP is intended to direct or influence independent clinical decision-making. Treatment decisions remain the responsibility of treating healthcare professionals and their patients

RFP Detail and Eligibility

RFP Intent and Scope	• The intent of this RFP is to request proposals for the implementation of strategies that will support and measurably improve equitable delivery of guideline concordant care for patients with HER2+ GEA in the United States, including the administration of HER2 directed therapy as part of first line treatment. • Proposals should describe the application of quality improvement standards to evaluate current adherence to treatment guidelines, evaluation of guideline-discordant care and measures to improve guideline-concordant care for patients with advanced HER2+ GEA. • Proposals should address equitable access to care and involve all stakeholders, including the patient community where appropriate. • Proposals should be designed to be sustainable, scalable, and transferable. • Proposed projects should be executed with the intent to disseminate the process and outcomes of the project with the broad oncology community involved in delivering care to this patient population. • Projects that improve knowledge of and access to precision medicine and that impact treatment centers in the community setting are encouraged
Eligibility	Geographic Scope: USA Applicant Eligibility Criteria: • The following may apply: ○ US healthcare delivery systems, academic and community oncology delivery networks ○ Applications from community cancer care providers are strongly encouraged. • Proposals must represent multi-disciplinary teams delivering care to GEA patients.

² Dayyani F, et al. *J Clin Oncol*. 2026;44(suppl 16; abstr 4053)

	• Collaboration among healthcare centers and organizations, especially community care providers, is encouraged to foster interactive sharing of knowledge and expertise • Proposals should include collaboration with patient advocates, advocacy organizations, of other groups that can represent the perspective of GEA patients. • Awards will be made only to eligible organizations and institutions. Individual healthcare professionals are not eligible to receive awards directly
Requirements	
<i>Date RFP Issued</i>	1 September 2026
<i>Clinical Area</i>	Oncology – advanced and metastatic HER2+ gastroesophageal adenocarcinoma (GEA)
<i>Area of Interest</i>	Topics of Interest Include but are not limited to: • Strategies to ensure implementation of guideline concordant care for patients with advanced HER2+ GEA • Equitable access to precision medicine for advanced HER2+ GEA patients • Use of clinical data to identify and address gaps in guideline-concordant care for HER2+ GEA patients. This may include treatment data, prescription patterns, and care patterns. • Establishing and enhancing multi-disciplinary teams to ensure GEA patients receive appropriate testing, treatment, and management • It is expected that projects will be evidence-based with planned evaluation of the impact of interventions that follow generally accepted scientific principles and are of the caliber to be presented at scientific meetings and published. • All proposals should include evidence of challenges present in the care delivery system and involve the patient population impacted as well as the cross functional care delivery team responsible for treatment. • All proposals should be designed to be sustainable beyond the grant funding period and be scalable to broader application following the project. • It is not the intention of the grant to fund the creation of roles in care delivery. • It is not our intent to support clinical research projects. Projects evaluating the efficacy/safety of therapeutic or diagnostic agents will not be considered
<i>Target Audience</i>	• Key stakeholders in GEA care including but not limited to oncologists and allied healthcare providers
<i>Expected Approximate Monetary Range of Grant Applications</i>	The total available budget for this RFP is \$1,000,000 USD Individual projects requesting up to \$125,000 USD will be considered The amount of the grant that the panel is prepared to fund for any project will depend upon the joint review panel's evaluation of the proposal and costs involved and will be stated clearly in the grant agreement
<i>Key Dates</i>	• RFP Release Date: 1 September 2026 • Full Proposal Date: 15 October 2026

	• Review of Full Proposals by Review Panel: 15 November 2026 • Anticipated full proposal notification date: end of November 2026 • Grants will be distributed following a fully executed agreement • Anticipated Project State and End Dates: January 2027 to December 2028
<i>How to Submit</i>	All applications must be submitted in accordance with the requirements and instructions of this Request for Proposals (RFP). All application materials must be in English and must be submitted online through the EveryGrant application portal. Please note, applicants will be prompted to create an account prior to submitting an application. No paper applications sent by mail, e-mail, or fax will be accepted.
<i>Review Process</i>	Jazz and Conquer Cancer will convene a Scientific Review Committee that will serve as the Expert Review Panel (ERP). The ERP will be composed of subject matter experts who will perform an independent and confidential peer review of all in-scope proposals. Jazz Pharmaceuticals will participate as a non-voting member of the ERP. The ERP's collective recommendations will determine which proposals are awarded funding. Jazz Pharmaceuticals will allocate funds upon ERP recommendations. Reviews will be based on the following criteria: • Impact and innovation of the proposed project • Approach and feasibility • Scalability, transferability, and sustainability • Organizational capacity and leadership • Adherence to the requirements set forth in this RFP
Full Application Instructions	
Eligibility Form	Applicants must complete the eligibility form to confirm they align with the criteria noted in this RFP. In addition, please confirm the program you are applying for. For this RFP, please select "Improving Guideline Concordant Care for Advanced HER2+ Gastroesophageal Adenocarcinoma."
Applicant Information	Please enter the information requested for the Principal Investigator of the project and upload a copy of the PI's NIH Biosketch or Science Experts Curriculum Vitae (SciENcv).
Project Information	Please enter your project title and summary/abstract where prompted. If the project will require an IRB, please provide the IRB approval status, assurance number, and approval/expiration dates.
Quality Improvement Proposal	Please upload a PDF file of your proposal with the following sections. Proposals must not exceed 10 pages . There is no minimum page requirement.
<i>Goals and Objectives</i>	Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s). List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target

	population as well as the outcomes you expect to achieve as a result of conducting the project
<i>Assessment of Need for the Project</i>	Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information
<i>Target Audience</i>	Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
<i>Project Design and Methods</i>	Describe the planned project and the way it addresses the established need. If your methods include educational activities, please describe succinctly the topic(s) and format of those activities
<i>Evaluation and Outcomes</i>	In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data. Quantify the amount of change expected from this project in terms of your target audience. Describe how the project outcomes will be broadly disseminated
<i>Anticipated Project Timelines</i>	Provide an anticipated timeline for your project including project start/end dates
<i>Organization Detail</i>	Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.
Description of QI Experience	Please provide a one-page summary of the PI or project teams prior relevant quality improvement experience.
Budget Detail	Please use the budget form provided in the online portal. All requested amounts must be in U.S. dollars (USD). When developing your budget please adhere to the following guidelines: • Indirect costs (e.g. institutional overhead) may be included in the requested budget, but are subject to approval by Jazz if selected. • Budget Cap: Total costs – including overhead – must not exceed the maximum budget limit of \$125,000 over a 24-month period.
Institutional Letter of Support	Please upload an institutional letter of support confirming your organization's commitment to the project and any allocated resources and confirmation of the PI's current position within the organization.
Collaboration Letters (optional)	Please upload letters from any collaborating organizations or investigators to support your project.

Additional Information (optional)	If there is any additional information you feel the ERP should be aware of concerning the importance of this project, please upload it here.
Applicant Organization Information	Principal Investigators must complete all applicant organization details within the online portal. This section is required for funding consideration; incomplete applications will be administratively disqualified. Please provide the following: • Organization Details: Legal name and full address • Organizational Classification: For-profit or nonprofit status • Tax ID: Employer Identification Number (EIN) • Authorized Signing Official Signature Page: Uploaded using the provided template

About Jazz Pharmaceuticals

Jazz Pharmaceuticals' purpose is to innovate to transform the lives of patients and their families.

Jazz is dedicated to developing life-changing medicines for people with rare diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what's possible – to make the “small wins” big again.

Jazz has a diverse portfolio of marketed medicines including leading therapies addressing rare epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics.

About Conquer Cancer, the ASCO Foundation

Conquer Cancer®, the ASCO Foundation, funds research for every cancer, every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than \$215 million through more than 10,500 grants and awards to improve cancer care and accelerate breakthroughs in clinical and translational oncology research. For more information visit CONQUER.ORG.

Powered by Conquer Cancer, EveryGrant® is a comprehensive grant management service that blends decades of grantmaking success with a global network of experts to help organizations design innovative funding programs—all without navigating the complexities of building them in-house. Contact us at EveryGrant@conquer.org.